Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.

Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations

Open access
Hausenloy, Derek J., Botker, Hans Erik, Engstrom, Thomas, Erlinge, David, Heusch, Gerd, Ibanez, Borja, Kloner, Robert A., Ovize, Michel, Yellon, Derek M., Garcia-Dorado, David·2016·European Heart Journal

Abstract

Ischaemic heart disease (IHD) remains the leading cause of death and disability in Europe and worldwide. A major cause of morbidity and mortality in IHD patients is an acute ST-segment elevation myocardial infarction (STEMI), which despite prompt reperfusion by primary percutaneous coronary intervention (PPCI) has significant mortality (7% death at 1 year) and morbidity (22% prolonged or new hospitalization for heart failure at 1 year) in patients with large infarcts.1 When high-risk STEMI patients presenting with cardiogenic shock are not excluded, mortality at 1 year is even higher, at 12% after 1 year.2 As such, there remains an urgent need to discover novel therapies which can be given prior to or at the time of PPCI to reduce myocardial infarct (MI) size in order to preserve left ventricular (LV) systolic function, prevent the onset of heart failure, and improve survival in reperfused STEMI patients. In patients presenting with STEMI, rapid access to the emergency medical services and timely reperfusion by PPCI minimize the total ischaemic time, a major determinant of MI size. Although myocardial reperfusion is essential to salvage myocardium following a STEMI, the process of restoring coronary blood flow to the ischaemic tissue can, in itself, induce myocardial injury and cardiomyocyte death, a phenomenon which is known as ‘myocardial reperfusion injury’.3,4 Crucially, there is currently no effective therapy for reducing myocardial reperfusion injury in STEMI patients, and therefore, it remains a valid target for cardioprotection. However, the search for an effective therapy capable of targeting myocardial reperfusion injury and reducing MI size has been quite challenging, with a large number of failures to translate novel cardioprotective therapies into the clinical setting.5,6 In this consensus article, we highlight the importance of myocardial reperfusion injury as a viable target for cardioprotection and discuss the potential reasons underlying the neutral results of recent clinical cardioprotection trials and explore the future possibilities for reducing MI size and improving clinical outcomes in patients with IHD. Main mechanisms of cardiomyocyte cell death during myocardial reperfusion and their inter-relations. The mitochondrial permeability transition pore (MPTP) is an important mediator of myocardial reperfusion injury,18 yet several aspects of its role remain obscure. It is not well understood how opening of the MPTP causes sarcolemmal rupture within the first few minutes of reperfusion. A potential link could be the development of hypercontracture, caused by high and oscillating Ca2+ in the presence of ATP.19 Calpain activation occurring upon normalization of intracellular pH in cells with Ca2+ has been demonstrated to contribute to cardiomyocyte death.20 Reactive oxygen species may induce MPTP opening, and interventions attenuating mitochondrial ROS production can prevent MPTP opening and reduce MI size,21 but they also have extra-mitochondrial targets, the importance of which needs to be clarified. A potentially important target of ROS is the tetrahydrobiopterin–eNOS complex, which may be dissociated by oxidation, resulting in peroxynitrite formation and reduced NO availability.22 Recent studies have proposed that RIP3-mediated programmed cell necrosis may play a role in myocardial reperfusion injury through CaMKII and the MPTP.23 Summary of the data available for several therapeutic interventions for targeting myocardial reperfusion injury and reducing myocardial infarct size Mechanism of cardioprotection known: +, known; +/−, not clear. Pre-clinical data shows consistent cardioprotection: +, consistent cardioprotection; +/−, inconsistent cardioprotection. Potential issues over safety: −, no known safety issues; +/−, potential safety issues. Clinical MI studies: ++, several positive MI studies; +, only one positive MI study; +/−, inconsistent MI studies; −, neutral MI studies. Meta-analysis data: +, positive data; +/−, inconsistent data. Clinical outcome studies: *, outcome study ongoing; −, neutral outcome study data. Summary of the data available for several therapeutic interventions for targeting myocardial reperfusion injury and reducing myocardial infarct size Mechanism of cardioprotection known: +, known; +/−, not clear. Pre-clinical data shows consistent cardioprotection: +, consistent cardioprotection; +/−, inconsistent cardioprotection. Potential issues over safety: −, no known safety issues; +/−, potential safety issues. Clinical MI studies: ++, several positive MI studies; +, only one positive MI study; +/−, inconsistent MI studies; −, neutral MI studies. Meta-analysis data: +, positive data; +/−, inconsistent data. Clinical outcome studies: *, outcome study ongoing; −, neutral outcome study data. Various time-windows for applying therapeutic strategies for reducing myocardial infarct size in STEMI patients undergoing PPCI. Zhao et al. first reported that brief episodes of is

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehw145

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 119 references

Cited by

See all 325

Metadata

Authors
Hausenloy, D. J., Botker, H. E., Engstrom, T., Erlinge, D., Heusch, G., Ibanez, B., Kloner, R. A., Ovize, M., Yellon, D. M., & Garcia-Dorado, D.
Venue
European Heart Journal
Published
2016-04-26
Volume
38
Issue
13
Pages
ehw145
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2345001578
Cited by
325
References
119
FWCI
32.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. https://app.cochat.ai/papers/10.1093/eurheartj/ehw145
The paper
Hausenloy, D. J., Botker, H. E., Engstrom, T., Erlinge, D., Heusch, G., Ibanez, B., Kloner, R. A., Ovize, M., Yellon, D. M., & Garcia-Dorado, D. (2016). Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.